详细说明
- Purity>90%, by SDS-PAGE with silver staining.
- Endotoxin Level<0.10 EU per 1 μg of the protein by the LAL method.
- ActivityMeasured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED 50 for this effect is typically 1-5 µg/mL.
- SourceHuman embryonic kidney cell, HEK293-derived
Human CD277/BTN3A1
(Phe31-Gly254)
Accession # O00481IEGRMD Human IgG1
(Pro100-Lys330)N-terminus C-terminus - Accession #
- N-terminal Sequence
AnalysisPhe31 - Structure / FormDisulfide-linked homodimer
- Predicted Molecular Mass51 kDa
- SDS-PAGE54-62 kDa, reducing conditions
8539-BT | | |
Formulation Lyophilized from a 0.2 μm filtered solution in PBS. | ||
Reconstitution Reconstitute at 100 μg/mL in PBS. | ||
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Bioactivity | Recombinant Human CD277/BTN3A inhibits anti-CD3 antibody-induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 1-5 µg/mL. |
SDS-PAGE | 1 μg/lane of RecombinantHuman CD277/BTN3A1 (Catalog # 8539-BT) was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by silverstaining, showing bands at 58.8 and 150 kDa, respectively. |
- References:
- Abeler-Dorner, L. et al. (2012) Trends Immunol. 33:34.
- Rhodes, D.A. et al. (2001) Genomics 71:351.
- Jeong, J. et al. (2009) J. Biol. Chem. 284:22444.
- Harly, C. et al. (2012) Blood 120:2269.
- Constant, P. et al. (1994) Science 264:267.
- Sandstrom, A. et al. (2014) Immunity 40:490.
- Harly, C. et al. (2015) Front. Immunol. 5:657.
- Bonneville, M. et al. (2006) Curr. Opin. Immunol. 18:539.
- Wang, H. et al. (2013) J.Immunol. 191:1029.
- Entrez Gene IDs:11119 (Human)
- Alternate Names:BT3.1; BTF5; BTN3A1; CD277